ARRY 382

Drug Profile

ARRY 382

Alternative Names: ARRY-382

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Cancer

Most Recent Events

  • 13 Nov 2017 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (PO)
  • 13 Nov 2017 Safety and efficacy data from a phase I/II trial in Solid tumours released by Array BioPharma
  • 04 Aug 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top